Profile data is unavailable for this security.
About the company
First Wave BioPharma, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the research and development of targeted, non-systemic therapies for the treatment of patients with gastrointestinal (GI) diseases. It is focused on developing a therapeutic pipeline with multiple late-stage clinical programs built around three proprietary technologies: Latiglutenase, a targeted oral biotherapeutic for celiac disease designed to breakdown gluten into non-immunogenic peptides; the biologic Adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency, and Capeserod, a selective 5-HT4 receptor partial agonist which the Company is developing as a gastroparesis therapeutic.
- Revenue in USD (TTM)0.00
- Net income in USD-6.44m
- Incorporated2014
- Employees15.00
- LocationEntero Therapeutics Inc777 Yamato Road, Suite 502BOCA RATON 33431United StatesUSA
- Phone+1 (561) 589-7020
- Websitehttps://enterothera.com/
More ▼
Mergers & acquisitions
| Acquired company | ENTO:NAQ since announced | Transaction value |
|---|---|---|
| ImmunogenX Inc | -90.50% | -- |
Data delayed at least 15 minutes, as of Oct 09 2024 20:59 BST.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Yield10 Bioscience Inc | 750.00k | -12.70m | 696.59k | 29.00 | -- | -- | -- | 0.9288 | -135.92 | -135.92 | 1.95 | -9.71 | 0.1697 | -- | -- | 25,862.07 | -287.44 | -91.26 | -- | -108.09 | -- | -- | -1,693.60 | -2,279.74 | -- | -- | -- | -- | -86.67 | -35.94 | -6.55 | -- | 1.84 | -- |
| Genprex Inc | 0.00 | -26.14m | 905.47k | 26.00 | -- | 0.2057 | -- | -- | -16.04 | -16.04 | 0.00 | 1.70 | 0.00 | -- | -- | 0.00 | -232.21 | -92.06 | -318.88 | -98.32 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -29.99 | -- | -7.13 | -- |
| LadRx Corp | 0.00 | -2.77m | 990.18k | 2.00 | -- | -- | -- | -- | -5.59 | -5.59 | 0.00 | -1.89 | 0.00 | -- | -- | 0.00 | -113.62 | -58.97 | -653.73 | -78.44 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 106.96 | -- | -- | -- |
| Entero Therapeutics Inc | 0.00 | -6.44m | 1.04m | 15.00 | -- | 0.0524 | -- | -- | -51.90 | -51.90 | 0.00 | 38.45 | 0.00 | -- | -- | 0.00 | -12.74 | -295.92 | -14.01 | -1,599.51 | -- | -- | -- | -- | -- | -265.69 | 0.0802 | -- | -- | -- | -7.55 | -- | -- | -- |
| Herborium Group, Inc. | 340.33k | -318.65k | 1.09m | 2.00 | -- | -- | -- | 3.21 | -0.3492 | -0.3492 | 0.3672 | -1.16 | 2.32 | 3.89 | 25.94 | -- | -216.97 | -490.56 | -- | -- | 58.31 | 56.36 | -93.63 | -186.81 | 0.0331 | -39.14 | -- | -- | 19.45 | -18.15 | 120.44 | -- | -- | -- |
| GRI Bio Inc | 0.00 | -8.28m | 1.16m | 4.00 | -- | 0.0671 | -- | -- | -100.69 | -100.69 | 0.00 | 5.88 | 0.00 | -- | -- | 0.00 | -130.64 | -192.93 | -187.01 | -353.99 | -- | -- | -- | -37,650.49 | -- | -- | 0.00 | -- | -- | -- | -85.61 | -- | 29.46 | -- |
| Axim Biotechnologies Inc | 92.90k | -4.14m | 1.21m | 6.00 | -- | -- | -- | 13.00 | -0.0163 | -0.0163 | 0.0003 | -0.0324 | 0.0233 | -- | -- | 15,483.33 | -103.73 | -154.34 | -- | -390.73 | 16.94 | -- | -4,451.97 | -36,362.71 | -- | -3.14 | -- | -- | 345.05 | -27.38 | -29.10 | -- | -- | -- |
| 180 Life Sciences Corp | 0.00 | -12.55m | 1.21m | 4.00 | -- | -- | -- | -- | -28.16 | -28.16 | 0.00 | -0.4439 | 0.00 | -- | -- | 0.00 | -142.80 | -42.39 | -270.23 | -56.41 | -- | -- | -- | -- | -- | -- | 18.20 | -- | -- | -- | 48.52 | -- | -- | -- |
| Trevena Inc | 443.00k | -37.03m | 1.25m | 23.00 | -- | -- | -- | 2.83 | -56.17 | -56.17 | 0.6391 | -22.23 | 0.0143 | -- | -- | 19,260.87 | -119.82 | -55.93 | -152.94 | -66.35 | -271.56 | -- | -8,358.24 | -3,134.41 | -- | -20.12 | 2.51 | -- | 847.61 | -11.43 | 24.93 | -- | -24.67 | -- |
| Seelos Therapeutics Inc | 2.01m | 4.09m | 1.40m | 8.00 | 0.0205 | -- | -- | 0.6927 | 156.15 | 156.15 | 22.91 | -135.50 | 0.2823 | -- | 6.51 | 134,266.70 | 57.34 | -180.05 | -- | -386.76 | -- | -- | 203.13 | -9,612.88 | -- | -608.33 | -- | -- | -- | -- | 48.48 | -- | -- | -- |
| Regen BioPharma Inc | 236.57k | -882.60k | 1.44m | 1.00 | -- | -- | -- | 6.10 | -0.2157 | -0.2157 | 0.0594 | -1.18 | 1.04 | -- | 3.82 | 236,570.00 | -407.33 | -104.36 | -- | -- | -- | -- | -392.01 | -275.00 | -- | -1.36 | -- | -- | 0.4416 | 18.79 | -58.11 | -- | -- | -- |
Data as of Oct 09 2024. Currency figures normalised to Entero Therapeutics Inc's reporting currency: US Dollar USD
1.84%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Armistice Capital LLCas of 31 Mar 2024 | 27.00k | 1.09% |
| Geode Capital Management LLCas of 30 Jun 2024 | 16.15k | 0.65% |
| Tower Research Capital LLCas of 31 Mar 2024 | 2.39k | 0.10% |
| Wells Fargo Bank, NA (Private Banking)as of 31 Mar 2024 | 12.00 | 0.00% |
| U.S. Bank NA (Cincinnati Ohio Investment Management)as of 30 Jun 2024 | 1.00 | 0.00% |
| Kathleen S. Wright Associates, Inc.as of 30 Jun 2024 | 1.00 | 0.00% |
| Wells Fargo Clearing Services LLCas of 31 Mar 2024 | 1.00 | 0.00% |
| UBS Securities LLCas of 31 Mar 2024 | 0.00 | 0.00% |
More ▼
Data from 31 Mar 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
